Phenobarbital (DB01174): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Phenobarbital is a long-acting barbituric acid derivative, classified as a sedative-hypnotic and anticonvulsant, that has occupied a significant, albeit evolving, role in clinical medicine for over a century. Its primary mechanism of action involves positive allosteric modulation of the gamma-aminobutyric acid type A (GABAA​) receptor, where it prolongs the opening of the associated chloride ion channel, leading to potent, nonselective depression of the central nervous system (CNS). This fundamental action underlies its broad-spectrum efficacy in the management of generalized tonic-clonic and partial seizures, making it one of the oldest and most enduring anti-seizure medications still in clinical use.

Therapeutically, Phenobarbital is indicated for various seizure disorders, status epilepticus, and short-term sedation. It also has critical, though often off-label, applications in the management of neonatal seizures, withdrawal syndromes from alcohol and other CNS depressants, and certain types of hyperbilirubinemia. Despite its proven efficacy and low cost—factors that have secured its place on the World Health Organization's List of Essential Medicines—its clinical utility is significantly constrained by a challenging safety and tolerability profile. Key limitations include a narrow therapeutic index, a high potential for physical dependence and severe withdrawal reactions, and a profound propensity for drug-drug interactions. As a potent inducer of hepatic cytochrome P450 (CYP450) enzymes, Phenobarbital accelerates the metabolism of numerous co-administered drugs, frequently leading to therapeutic failure of those agents. Furthermore, its use is associated with significant CNS adverse effects, including sedation and cognitive impairment, as well as rare but life-threatening hypersensitivity reactions. Its status as a globally controlled substance (e.g., Schedule IV in the United States) further complicates its accessibility, creating a fundamental tension between its indispensable role in resource-limited settings and the regulatory imperatives to prevent its misuse. This monograph provides an exhaustive review of Phenobarbital's chemical properties, pharmacology, clinical applications, and regulatory status, contextualizing its enduring legacy within the landscape of modern therapeutics.

Introduction and Historical Significance

Phenobarbital represents a landmark molecule in the history of neurology and pharmacology, serving as a bridge between the empirical treatments of the 19th century and the mechanism-driven drug discovery of the modern era. Its introduction fundamentally altered the therapeutic landscape for epilepsy, a condition for which treatment options were previously limited and highly toxic.

Discovery and Development

The genesis of Phenobarbital lies in the broader development of barbiturates by German chemists at the turn of the 20th century. Following the synthesis of the first barbiturate, barbital, in 1902 by Emil Fischer and Joseph von Mering, Fischer synthesized several related compounds, including Phenobarbital, by 1904.[1] The pharmaceutical company Bayer brought Phenobarbital to market in 1912 under the trade name Luminal, initially capitalizing on the well-established sedative and hypnotic properties of the barbiturate class.[1] At the time of its release, its profound anticonvulsant properties were unknown.

The Serendipitous Discovery of Anticonvulsant Properties

The discovery of Phenobarbital's anti-seizure efficacy is a classic example of serendipity in clinical medicine. In 1912, Alfred Hauptmann, a young physician in Freiburg, Germany, administered Luminal to his patients with epilepsy not to treat their seizures, but as a sedative to quell the disruptive nocturnal convulsions that disturbed the ward.[3] He observed that the drug not only induced sleep but also dramatically suppressed the seizures themselves.[2] Hauptmann's subsequent systematic study revealed remarkable improvements in seizure control and the overall physical and mental well-being of his patients, establishing Phenobarbital as a revolutionary therapeutic agent.[2] This discovery provided the first highly effective and better-tolerated alternative to the inorganic bromide salts, which had been the standard of care since 1857 but were associated with severe toxicity.[7]

Historical Context and Enduring Legacy

Phenobarbital is the oldest anti-seizure medication (ASM) still in widespread clinical use, a testament to its robust efficacy.[1] For decades, it was a first-line therapy for many forms of epilepsy. Its dominance began to wane in developed nations with the introduction of benzodiazepines in the 1960s and the subsequent development of newer generations of ASMs that offered improved safety and tolerability profiles.[1]

Global Health Perspective

Despite its decline in high-income countries, Phenobarbital's legacy endures, particularly from a global health perspective. Its inclusion on the World Health Organization's (WHO) List of Essential Medicines underscores its continued importance.[1] The WHO strongly recommends Phenobarbital as a first-line option for convulsive epilepsy in adults and children in resource-limited settings, a recommendation predicated on its proven efficacy, broad-spectrum activity, and exceptionally low cost.[1] This creates a notable dichotomy in global standards of care, where the choice between Phenobarbital and newer, more expensive agents is often dictated by economic factors rather than purely clinical ones. This situation highlights a complex trade-off between accessibility and tolerability in global health policy, sometimes described as putting "a hierarchy on the brain".[5]

Regulatory Evolution

Phenobarbital's long history also places it in a unique regulatory position. It was marketed in the United States before the passage of the Federal Food, Drug, and Cosmetic Act of 1938, which mandated that manufacturers provide evidence of safety for new drugs.[12] As a result, Phenobarbital was "grandfathered" into the pharmacopeia and is technically considered an "unapproved drug" by the Food and Drug Administration (FDA) for many of its long-standing uses.[12] This regulatory gap has only recently begun to be addressed. For example, the 2022 FDA approval of a specific injectable formulation, SEZABY (phenobarbital sodium), for the treatment of neonatal seizures marks a significant step in modernizing the regulatory status of this centenarian drug and formally validating a use that had been the de facto standard of care for decades.[12]

Chemical Identity and Physicochemical Properties

A precise understanding of Phenobarbital's chemical and physical properties is fundamental to its pharmacology, formulation, and clinical application. As a member of the barbiturate class, its structure is based on a barbituric acid core substituted at the C-5 position with both an ethyl and a phenyl group, which confers its specific pharmacological characteristics.[15]

Systematic Identification

Phenobarbital is identified across numerous chemical, regulatory, and biomedical databases. Its unique identifiers ensure unambiguous reference in clinical, research, and industrial contexts. The sodium salt of Phenobarbital (CAS Number: 57-30-7) is also commonly used, particularly for parenteral formulations, due to its greater water solubility compared to the parent acid.[15] A consolidated list of its primary identifiers is provided in Table 1.

Physical and Chemical Characteristics

Phenobarbital presents as an odorless, white crystalline powder or as colorless crystals.[15] It has a slightly bitter taste and exists in at least three different polymorphic crystalline forms.[15] A saturated aqueous solution of Phenobarbital is acidic, with a pH of approximately 5.[15] Its pKa is 7.41, and it has low lipid solubility compared to other barbiturates, a property that influences its pharmacokinetic profile, particularly its slower onset of action and longer duration.[17]

Identifier	Value	Source(s)
DrugBank ID	DB01174	15
Type	Small Molecule	18
CAS Number	50-06-6	15
IUPAC Name	5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione	15
Chemical Formula	C12​H12​N2​O3​	18
Average Molecular Weight	232.2353 g/mol	18
Monoisotopic Mass	232.08479226 Da	18
Canonical SMILES	CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2	15
InChIKey	DDBREPKUVSBGFI-UHFFFAOYSA-N	15
UNII (Unique Ingredient Identifier)	YQE403BP4D	1
DEA Code Number	2285	15
Physical Description	Odorless, white crystalline powder or colorless crystals; slightly bitter taste.	15

Clinical Pharmacology

The clinical effects of Phenobarbital are a direct consequence of its interactions with neuronal signaling pathways and its disposition within the body. Its pharmacodynamic profile is characterized by potent, multi-target CNS depression, while its pharmacokinetic profile is defined by slow absorption and an exceptionally long elimination half-life.

Pharmacodynamics: Mechanism of Action

Phenobarbital exerts its effects through a combination of mechanisms that collectively suppress neuronal excitability, making it a powerful anticonvulsant and sedative-hypnotic.

Primary Mechanism: GABA-A Receptor Modulation

The principal mechanism of action for Phenobarbital is the positive allosteric modulation of the GABAA​ receptor, the primary inhibitory neurotransmitter receptor in the CNS.[1] The

GABAA​ receptor is a ligand-gated ion channel that, upon activation by GABA, becomes permeable to chloride ions (Cl−).[27] The resulting influx of chloride hyperpolarizes the postsynaptic neuron, making it less likely to fire an action potential and thus producing an inhibitory effect.[1]

Phenobarbital binds to a distinct allosteric site on the GABAA​ receptor complex, separate from the binding sites for GABA and for benzodiazepines.[26] Its modulatory effect is mechanistically different from that of benzodiazepines. While benzodiazepines increase the

frequency of chloride channel opening in the presence of GABA, Phenobarbital and other barbiturates increase the duration of time the channel remains open for each binding event.[25] This prolonged channel opening allows for a greater and more sustained influx of chloride ions, resulting in a more profound and lasting hyperpolarization of the neuron.[1]

This specific molecular action is directly responsible for both the high efficacy and the significant toxicity of Phenobarbital. At higher therapeutic concentrations, and particularly in overdose situations, barbiturates can directly activate the GABAA​ receptor channel even in the absence of GABA.[29] This direct agonistic activity, combined with the prolonged channel opening, means there is no "ceiling effect" to their CNS depression. This lack of a ceiling is the fundamental pharmacodynamic reason for the narrow therapeutic index of barbiturates and their potential to cause severe respiratory depression, coma, and death in overdose, a risk not shared by benzodiazepines, which are dependent on the presence of endogenous GABA for their effect.

Secondary and Contributing Mechanisms

In addition to its primary action on the GABAA​ receptor, Phenobarbital's broad anticonvulsant effects are augmented by its influence on excitatory neurotransmission. It has been shown to inhibit glutamate-induced depolarizations, likely by acting as an antagonist at excitatory amino acid receptors such as the AMPA and kainate receptors.[1] Furthermore, Phenobarbital may inhibit voltage-gated calcium channels, an action that would reduce the presynaptic release of excitatory neurotransmitters.[18] This dual approach—enhancing the primary inhibitory system (GABA) while simultaneously suppressing the primary excitatory system (glutamate)—creates a powerful and synergistic depression of neuronal hyperexcitability. This multi-target profile likely explains its efficacy across a broad spectrum of seizure types.

Site of Action

The sedative-hypnotic effects of Phenobarbital are thought to arise from its action on the polysynaptic midbrain reticular formation, a key area of the brainstem that controls CNS arousal and wakefulness.[18] By depressing activity in this region, Phenobarbital produces its characteristic sedative effects.

Pharmacokinetics: ADME Profile

The pharmacokinetic profile of Phenobarbital is characterized by slow but complete absorption, wide distribution, extensive hepatic metabolism, and a remarkably long elimination half-life, which has significant clinical implications for dosing, time to steady-state, and management of toxicity.

Absorption

Phenobarbital is absorbed to varying degrees following oral, rectal, or parenteral (intramuscular or intravenous) administration.[18] Oral bioavailability is high, at approximately 90%.[1] However, absorption from the gastrointestinal tract is relatively slow, with peak plasma concentrations (

Cmax​) typically reached 8 to 12 hours after an oral dose.[1] In contrast, following intravenous administration for emergent situations like status epilepticus, the onset of action occurs within 5 minutes, with maximum effects achieved within 30 minutes.[1] The sodium salt of Phenobarbital is more rapidly absorbed than the acid form, and absorption is enhanced when taken as a dilute solution or on an empty stomach.[18]

Distribution

Following absorption, Phenobarbital is rapidly and widely distributed to all tissues and fluids, including the brain.[25] It exhibits low to moderate plasma protein binding, with estimates ranging from 20% to 45%.[1] Due to its chemical properties, it readily crosses the placental barrier and is distributed throughout fetal tissues, with high concentrations found in the placenta, fetal liver, and brain.[25] It is also excreted into breast milk.[1]

Metabolism

Phenobarbital is extensively metabolized in the liver, primarily through oxidation by the cytochrome P450 (CYP450) microsomal enzyme system.[1] The principal isoenzyme responsible for its metabolism is CYP2C9, with minor metabolic pathways involving CYP2C19 and CYP2E1.[30] The primary metabolite is the inactive p-hydroxyphenobarbital, which is subsequently conjugated with glucuronic acid or sulfate to form water-soluble compounds for excretion.[17] Phenobarbital itself is an active metabolite of the anticonvulsant drug primidone, which is converted to Phenobarbital and phenylethylmalonamide (PEMA) in the body.[34]

Excretion

Elimination of Phenobarbital occurs primarily through the kidneys.[1] A significant fraction of the drug, approximately 25% to 50%, is excreted unchanged in the urine, with the remainder eliminated as hepatic metabolites.[17] The renal excretion of unchanged Phenobarbital is pH-dependent. Because it is a weak acid, alkalinization of the urine increases its ionization, which traps the drug in the renal tubules and prevents its reabsorption, thereby enhancing its elimination.[1] This principle historically formed the basis for using forced alkaline diuresis in the management of overdose, though the clinical utility of this practice is now debated due to risks of fluid overload and limited efficacy compared to other methods.[37]

The most clinically significant pharmacokinetic parameter of Phenobarbital is its exceptionally long and variable elimination half-life (t1/2​), which ranges from 53 to 118 hours (approximately 2 to 5 days) in adults, with a mean of around 79 hours.[1] The half-life can be even longer in neonates, ranging from 60 to 180 hours.[39] This long half-life has dual implications. On one hand, it allows for convenient once-daily dosing, which can improve patient adherence, and it promotes relatively stable plasma concentrations.[10] On the other hand, it means that achieving steady-state plasma concentrations can take 3 to 4 weeks, which complicates dose titration and delays the assessment of full therapeutic effect.[17] Furthermore, in the event of an overdose, the long half-life contributes to a prolonged period of toxicity, often requiring extended supportive care.[38]

Therapeutic Applications

Phenobarbital's potent CNS depressant and anticonvulsant properties have led to its use in a variety of clinical settings, ranging from the chronic management of epilepsy to the acute treatment of medical emergencies. Its applications can be categorized into primary, often FDA-approved indications, and significant off-label or specialized uses that leverage its unique pharmacological profile.

Approved and Primary Clinical Indications

Seizure Disorders

The foremost indication for Phenobarbital is the management of seizure disorders.[18] It is effective against generalized tonic-clonic seizures and partial (focal) seizures.[1] Its broad-spectrum activity makes it a versatile agent, although it is notably ineffective and may even exacerbate absence (petit mal) seizures.[1] While newer ASMs with better tolerability are now preferred as first-line agents in many developed countries, Phenobarbital's efficacy is comparable to that of phenytoin and carbamazepine.[1] It remains a crucial first-line therapy for neonatal seizures, a context in which its long history of use has established it as the standard of care, despite this use being historically off-label until the recent approval of a specific formulation.[1]

Status Epilepticus

Phenobarbital is an important agent in the management of status epilepticus, a neurological emergency characterized by prolonged or recurrent seizures.[25] It is typically employed as a second-line or third-line therapy after initial treatment with benzodiazepines and phenytoin has failed to terminate the seizure activity.[1] It is administered intravenously in this setting, with a loading dose of 15-20 mg/kg in adults.[25]

Sedation and Hypnosis

Phenobarbital is indicated for its sedative-hypnotic properties, including the short-term treatment of insomnia and the relief of anxiety, tension, and apprehension.[21] It is also used to provide pre-operative sedation.[1] However, due to its significant side-effect profile, potential for dependence, and the development of tolerance to its hypnotic effects after about two weeks, its use for these indications has been largely supplanted by safer alternatives, primarily benzodiazepines.[1]

Off-Label and Specialized Uses

Withdrawal Syndromes

The principle of cross-tolerance between CNS depressants makes Phenobarbital a valuable tool for managing withdrawal syndromes. It is used to prevent and treat the potentially life-threatening symptoms of withdrawal from chronic use of alcohol, benzodiazepines, and other barbiturates.[1] By substituting a long-acting GABAergic agent (Phenobarbital) for a shorter-acting substance, clinicians can stabilize the patient's neurological state and then implement a slow, controlled taper of the Phenobarbital dose, thereby mitigating the risk of severe withdrawal symptoms such as seizures and delirium.

Hyperbilirubinemia

Phenobarbital is used in low doses to treat unconjugated hyperbilirubinemia.[18] It acts as an inducer of the hepatic enzyme UDP-glucuronosyltransferase (UGT1A1), which is responsible for conjugating bilirubin. By enhancing the activity of this enzyme, Phenobarbital increases the clearance of bilirubin from the body. This makes it useful in the management of neonatal jaundice and in patients with certain genetic disorders characterized by impaired bilirubin conjugation, such as Crigler-Najjar syndrome type II and Gilbert's syndrome.[1]

Palliative Care

In the context of end-of-life care, Phenobarbital is sometimes used by specialists to manage refractory terminal agitation and intractable seizures when other agents have failed.[49] Its potent sedative properties can provide comfort to patients in their final days.

Physician-Assisted Suicide

In jurisdictions where physician-assisted suicide is legally permitted, massive doses of Phenobarbital are prescribed to terminally ill individuals to allow them to end their life.[1]

Safety Profile, Contraindications, and Toxicology

The clinical use of Phenobarbital is fundamentally limited by its narrow therapeutic index and a significant burden of adverse effects, contraindications, and potential for severe toxicity. A thorough understanding of this risk profile is essential for its safe administration.

Adverse Drug Reactions

Adverse effects associated with Phenobarbital are common and range from mild, dose-dependent CNS effects to rare, but life-threatening, systemic reactions.

Common and Dose-Dependent Effects

The most frequently reported adverse reactions are extensions of Phenobarbital's primary pharmacological action on the CNS. These include somnolence, drowsiness, sedation, dizziness, ataxia (loss of coordination), and cognitive impairment such as difficulties with memory and concentration.[1] A residual sedative or "hangover" effect is also common, particularly with hypnotic doses.[53]

Paradoxical Reactions

In certain populations, particularly children and the elderly, Phenobarbital can produce paradoxical reactions. Instead of sedation, patients may experience excitement, agitation, confusion, irritability, or hyperactivity.[1]

Serious and Life-Threatening Reactions

• Respiratory Depression: Dose-dependent depression of the medullary respiratory center is a primary toxicity of all barbiturates. This can manifest as slowed or shallow breathing (bradypnea) and can progress to apnea, particularly with rapid intravenous administration, in overdose, or when combined with other CNS depressants.[18] A boxed warning for the injectable formulation (SEZABY) highlights the risk of profound sedation, respiratory depression, coma, and death when used concomitantly with opioids.[56]
• Severe Dermatologic Reactions: Although rare, Phenobarbital can induce severe and potentially fatal cutaneous hypersensitivity reactions. These include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and exfoliative dermatitis.[25] These conditions are medical emergencies requiring immediate discontinuation of the drug. Clinicians are advised to discontinue Phenobarbital at the first sign of a rash, unless it is clearly not drug-related.[56]
• Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Also known as multiorgan hypersensitivity, DRESS is a rare but severe reaction characterized by fever, rash, eosinophilia, and systemic organ involvement (e.g., hepatitis, nephritis). It can be life-threatening and requires immediate drug withdrawal and supportive care.[50]

Long-Term Effects

Chronic administration of Phenobarbital is associated with several adverse effects. Because it induces hepatic enzymes involved in vitamin metabolism, long-term use can lead to megaloblastic anemia from folate deficiency and osteomalacia or osteopenia from accelerated degradation of vitamin D.[25] Chronic cognitive impairment, depression, and mood changes are also well-documented.[46]

Dependence and Withdrawal

Phenobarbital is a habit-forming substance with a high potential for producing physical and psychological dependence, especially with prolonged use of high doses.[14] Tolerance develops to the sedative effects, often leading users to escalate their dose.[51] Abrupt discontinuation after chronic use can precipitate a severe and potentially fatal withdrawal syndrome. Symptoms typically begin 8 to 12 hours after the last dose and include anxiety, muscle twitching, tremors, weakness, nausea, vomiting, insomnia, and orthostatic hypotension. This can progress to major withdrawal symptoms, including delirium, convulsions (status epilepticus), and cardiovascular collapse.[25] Therefore, withdrawal from Phenobarbital must be conducted gradually under medical supervision.

Contraindications and High-Risk Populations

The use of Phenobarbital is strictly contraindicated in certain patient populations due to an unacceptable risk of severe adverse events.

Absolute Contraindications

• Hypersensitivity: Known hypersensitivity to Phenobarbital or any other barbiturate is an absolute contraindication.[14]
• Porphyria: Phenobarbital is strictly contraindicated in patients with a history of manifest or latent acute intermittent porphyria or porphyria variegata.[1] This is a classic example of a pharmacogenetic contraindication. Phenobarbital induces the enzyme delta-aminolevulinic acid (ALA) synthase, the rate-limiting enzyme in the heme synthesis pathway.[61] In individuals with a genetic deficiency of a downstream enzyme in this pathway (as in the porphyrias), this induction leads to a massive accumulation of neurotoxic porphyrin precursors (ALA and porphobilinogen), which can precipitate a life-threatening acute porphyric attack.[61]
• Severe Hepatic Impairment: As Phenobarbital is extensively metabolized by the liver, its use is contraindicated in patients with severe hepatic dysfunction or hepatic coma, where its clearance would be impaired, leading to drug accumulation and toxicity.[25]
• Severe Respiratory Disease: Given its potent respiratory depressant effects, Phenobarbital is contraindicated in patients with severe respiratory disease where dyspnea or obstruction is evident, such as severe chronic obstructive pulmonary disease (COPD) or status asthmaticus.[1]

High-Risk Populations and Precautions

• Pregnancy and Lactation: Phenobarbital is classified as FDA Pregnancy Category D, indicating positive evidence of human fetal risk.[25] It readily crosses the placenta and has been associated with an increased incidence of fetal abnormalities ("fetal hydantoin syndrome"-like effects) and can cause a neonatal withdrawal syndrome characterized by seizures and hyperirritability.[1] It is also excreted in breast milk and can cause sedation, lethargy, and poor feeding in the nursing infant.[1]
• Elderly and Debilitated Patients: These patients are more sensitive to the CNS effects of Phenobarbital and may experience marked confusion, depression, or paradoxical excitement. Dosage reduction is recommended.[1]
• Renal Impairment: Since a substantial portion of the drug is excreted unchanged by the kidneys, patients with impaired renal function require dosage adjustments to prevent accumulation.[36]

Overdose and Management

Acute Phenobarbital overdose is a medical emergency that can rapidly lead to profound coma and death. The management of toxicity is a critical aspect of its clinical profile.

Signs and Symptoms of Toxicity

Phenobarbital overdose results in an exaggeration of its pharmacodynamic effects, leading to a global depression of bodily functions.[1] The clinical presentation, often referred to as a sedative-hypnotic toxidrome, includes a progression of symptoms.[65] Initial signs may include lethargy, slurred speech (dysarthria), ataxia, and nystagmus.[66] As toxicity worsens, this progresses to a decreased level of consciousness (stupor) and eventually deep coma with areflexia.[18]

The most life-threatening consequences are respiratory and cardiovascular depression. Respiratory effort becomes slow and shallow (Cheyne-Stokes respiration) and can cease entirely (apnea).[1] Cardiovascular effects include bradycardia and severe hypotension, which can lead to circulatory collapse and shock.[1] Other characteristic signs include hypothermia and the formation of "barbiturate blisters" on the skin over pressure points.[1] In cases of severe intoxication, the profound CNS depression can mimic brain death, with loss of brainstem reflexes and an isoelectric or burst-suppression pattern on electroencephalogram (EEG).[1] Lethal serum concentrations are generally considered to be in excess of 80 mcg/mL, though toxicity can occur at lower levels.[17]

Management Principles

There is no specific antidote or reversal agent for Phenobarbital poisoning.[1] Therefore, management is entirely supportive and focused on maintaining vital functions and enhancing drug elimination.

• Airway, Breathing, and Circulation (ABC) Support: The immediate priority is the stabilization of the patient. This involves aggressive airway management, often requiring early endotracheal intubation and mechanical ventilation to protect against aspiration and manage respiratory failure.[1] Circulatory support with intravenous fluids and, if necessary, vasopressor agents is critical to manage hypotension and prevent shock.[1]
• Enhanced Elimination: After the patient is stabilized, measures to accelerate the removal of Phenobarbital from the body are considered.
• Multi-Dose Activated Charcoal (MDAC): Phenobarbital undergoes enterohepatic and enteroenteric recirculation. MDAC, administered via a nasogastric tube, can interrupt this process by adsorbing the drug in the gut, thereby increasing its non-renal clearance and potentially shortening the duration of coma. It is a mainstay of treatment in significant ingestions.[1]
• Extracorporeal Removal (Hemodialysis): In cases of severe poisoning—characterized by refractory hypotension, respiratory failure requiring prolonged ventilation, or extremely high or rising serum concentrations (e.g., >100 mg/L or 430 micromol/L)—extracorporeal methods are employed.[38] Hemodialysis is highly effective and can reduce the elimination half-life by up to 90%, significantly accelerating recovery.[1]
• Forced Alkaline Diuresis: While historically advocated based on the principle of pH-dependent renal excretion, this method is now generally not recommended. Its efficacy is limited, and it carries substantial risks of fluid overload, electrolyte disturbances, and cerebral edema, which often outweigh its potential benefits.[25]

Clinically Significant Drug Interactions

Phenobarbital is notorious for its extensive and clinically significant drug-drug interactions. These interactions are primarily driven by its potent induction of hepatic metabolic enzymes but also include important pharmacodynamic effects. Failure to recognize and manage these interactions can lead to therapeutic failure of concomitant medications or additive toxicity.

Metabolic Interactions (Pharmacokinetic)

The most critical aspect of Phenobarbital's interaction profile is its role as a potent, broad-spectrum inducer of hepatic microsomal enzymes.[1] It activates nuclear receptors (e.g., CAR/RXR) that upregulate the transcription of numerous genes involved in drug metabolism, most notably the cytochrome P450 (CYP450) isoenzymes and UDP-glucuronosyltransferases (UGTs).[1] Key induced enzymes include CYP2B6, CYP2C9, CYP2C19, and CYP3A4.[1]

The clinical consequence of this enzyme induction is the accelerated metabolism and clearance of a vast number of co-administered drugs that are substrates for these enzymes. This leads to lower plasma concentrations of the affected drugs and a high risk of therapeutic failure.[18] The onset of induction is gradual, and its effects can persist for weeks after Phenobarbital is discontinued. Conversely, certain drugs can inhibit the metabolism of Phenobarbital, leading to increased levels and potential toxicity.[18] Table 2 summarizes some of the most critical metabolic interactions.

Pharmacodynamic Interactions

Phenobarbital exhibits additive or synergistic pharmacodynamic interactions when co-administered with other CNS depressant drugs. This leads to an increased risk of sedation, cognitive and motor impairment, respiratory depression, coma, and death.[51] This is particularly dangerous with:

• Alcohol: The combination is notoriously hazardous and should be strictly avoided.[25]
• Opioids: This combination carries a high risk of fatal respiratory depression and is the subject of a US Boxed Warning.[14]
• Benzodiazepines: Additive sedation and respiratory depression are significant concerns.[71]
• Other Sedatives/Hypnotics, Tranquilizers, and Antihistamines: All can potentiate the CNS depressant effects of Phenobarbital.[51]

Absorption Interactions

The absorption of Phenobarbital can be reduced by co-administration of certain substances. For example, aluminum-containing antacids can decrease its absorption from the gastrointestinal tract, potentially leading to reduced serum concentrations and diminished efficacy.[18]

Interacting Drug/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Oral Contraceptives (Estrogens/Progestins)	Induction of CYP3A4 metabolism	Decreased contraceptive efficacy, risk of unintended pregnancy.	Advise patient to use non-hormonal or alternative, highly effective contraceptive methods (e.g., IUD, depot injection).14
Warfarin and other oral anticoagulants	Induction of CYP2C9 metabolism	Decreased anticoagulant effect, increased risk of thrombosis.	Monitor International Normalized Ratio (INR) closely, especially when starting, stopping, or changing the dose of Phenobarbital. Significant increases in the anticoagulant dose may be required.25
Other Anti-Seizure Medications (e.g., Phenytoin, Carbamazepine, Valproic Acid, Lamotrigine)	Complex interactions involving enzyme induction and/or inhibition	Unpredictable changes in serum concentrations of both Phenobarbital and the co-administered drug, leading to potential toxicity or loss of seizure control.	Therapeutic drug monitoring of all ASMs is essential. Dose adjustments should be guided by serum levels and clinical response.10
Corticosteroids (e.g., Prednisone, Dexamethasone)	Induction of CYP3A4 metabolism	Decreased therapeutic effect of the corticosteroid.	Monitor for reduced efficacy of the steroid; dose increases may be necessary.55
HIV Protease Inhibitors & NNRTIs (e.g., Atazanavir, Darunavir, Doravirine)	Potent induction of CYP3A4 metabolism	Markedly decreased plasma concentrations of the antiretroviral agent, leading to loss of virologic response and development of drug resistance.	Co-administration is often contraindicated. Consult specific antiretroviral prescribing information.74
Direct Oral Anticoagulants (DOACs) (e.g., Apixaban, Rivaroxaban)	Induction of CYP3A4 and/or P-glycoprotein	Decreased plasma concentrations and reduced anticoagulant effect.	Avoid combination if possible, especially in patients at high risk of thrombosis. Monitor for signs of thrombosis.18
Immunosuppressants (e.g., Cyclosporine, Tacrolimus, Sirolimus)	Induction of CYP3A4 metabolism	Decreased immunosuppressant levels, increasing the risk of organ transplant rejection.	Frequent therapeutic drug monitoring and significant dose increases of the immunosuppressant are required.18
Alcohol, Opioids, Benzodiazepines	Additive pharmacodynamic CNS depression	Increased risk of profound sedation, respiratory depression, coma, and death.	Avoid combination. If concomitant use is unavoidable (e.g., opioids for severe pain), limit dosages and durations to the minimum required and monitor patients closely for signs of respiratory depression and sedation.25

Regulatory Framework and International Status

Due to its therapeutic utility, coupled with a significant potential for abuse and physical dependence, Phenobarbital is classified as a controlled substance in most countries. Its regulatory status reflects a global effort to balance legitimate medical access with the prevention of diversion and misuse.

Controlled Substance Classification

Phenobarbital's capacity to produce psychological and physical dependence has led to its scheduling under national and international drug control laws.[14] This classification imposes strict legal controls on its manufacture, prescription, and dispensing.

This legal framework creates a significant tension, particularly in global health. The World Health Organization has designated Phenobarbital as an essential medicine, indispensable for the treatment of epilepsy, especially in low- and middle-income countries.[76] However, its status as a controlled substance can create substantial administrative, logistical, and political barriers to its procurement and distribution, paradoxically limiting access in the very regions where it is most needed.[77] This highlights a systemic conflict between public health imperatives and drug control policies that can impede the treatment of a major neurological disorder.

Table 3 provides a summary of its legal status in several key jurisdictions.

Jurisdiction/Body	Schedule/Classification	Key Implications	Source(s)
United States	DEA Schedule IV	Prescription required; limits on refills; record-keeping mandates; recognized medical use with a lower potential for abuse relative to Schedule III substances.	15
United Kingdom	Class B / Schedule 3	Possession without a prescription is illegal. Subject to prescription requirements for controlled drugs, but exempt from safe custody and register-keeping rules in some settings.	1
Canada	Schedule IV (under the Controlled Drugs and Substances Act)	Prescription required; subject to federal drug control statute regulating possession, trafficking, import, and export.	1
International (UN)	Schedule IV (under the 1971 Convention on Psychotropic Substances)	Recognized medical use but requires international controls on manufacture, trade, and distribution to prevent diversion and abuse.	77

Conclusion: The Enduring Role of a Centenarian Drug

For more than a century, Phenobarbital has remained a cornerstone of neurologic and psychiatric pharmacotherapy. Its history charts the course of modern drug development, from its serendipitous discovery as an anticonvulsant to its current, complex position in global medicine. Its potent, multi-target mechanism of action—primarily through enhancing GABAergic inhibition—confers a robust, broad-spectrum efficacy against convulsive seizures that has yet to be significantly surpassed, even by newer agents. This efficacy, combined with its low cost, has cemented its status as an indispensable medicine on the WHO's essential list, making it a life-saving therapy for millions in resource-limited settings.

However, the very properties that make Phenobarbital so effective also contribute to its significant liabilities. Its narrow therapeutic index, profound CNS and respiratory depression in overdose, and high potential for physical dependence and severe withdrawal demand cautious and expert clinical management. Furthermore, its role as one of the most potent inducers of hepatic enzymes creates a minefield of drug-drug interactions, complicating polypharmacy and risking the therapeutic failure of numerous other essential medications.

This duality defines Phenobarbital's modern legacy. In high-income nations, it has been largely relegated to second or third-line therapy for specific, refractory conditions, such as status epilepticus and neonatal seizures, having been superseded by agents with more favorable safety and tolerability profiles. Yet, globally, it remains a first-line, indispensable treatment. The story of Phenobarbital is therefore not merely that of a single molecule, but a larger narrative about the evolution of pharmacology, the shifting paradigms of risk-benefit analysis, and the stark realities of global health disparities. It serves as a powerful reminder that in medicine, the "best" drug is often a function of context, and that even in an era of precision medicine, the utility of a centenarian drug can be both enduring and essential.

Works cited

1. Phenobarbital - Wikipedia, accessed August 29, 2025, https://en.wikipedia.org/wiki/Phenobarbital
2. Phenobarbital - Bionity, accessed August 29, 2025, https://www.bionity.com/en/encyclopedia/Phenobarbital.html
3. Phenobarbital, accessed August 29, 2025, https://www.ilae.org/03DAE751-7CFC-11E7-BE53141877632E8F
4. A century of barbiturates in neurology - IMR Press, accessed August 29, 2025, https://www.imrpress.com/journal/RN/39/8/10.33588/rn.3908.2004428
5. the story of phenobarbital therapy in epilepsy in the last 100 years - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/23205960/
6. The history of barbiturates a century after their clinical introduction - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/
7. Brief history of anti-seizure drug development - eScholarship, accessed August 29, 2025, https://escholarship.org/content/qt8d83w75t/qt8d83w75t_noSplash_6503050bf33836cdb3f267f3fc41824e.pdf
8. History of Medications - Epilepsy Ontario, accessed August 29, 2025, https://epilepsyontario.org/about-epilepsy/treatments/medications/history/
9. History of epilepsy: The modern era - Epsy Health, accessed August 29, 2025, https://www.epsyhealth.com/seizure-epilepsy-blog/history-of-epilepsy-the-modern-era
10. Phenobarbital | Anti-Seizure Medication - Epilepsy Foundation, accessed August 29, 2025, https://www.epilepsy.com/tools-resources/seizure-medication-list/phenobarbital
11. History of Barbiturates - Narconon, accessed August 29, 2025, https://www.narconon.org/drug-information/barbiturates-history.html
12. 215910Orig1s000 OTHER REVIEW(S) - accessdata.fda.gov, accessed August 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215910Orig1s000OtherR.pdf
13. Phenobarbital: Seizure Uses, Warnings, Side Effects, Dosage - MedicineNet, accessed August 29, 2025, https://www.medicinenet.com/phenobarbital/article.htm
14. Phenobarbital (Luminal, Solfoton) - Epilepsy Medication, accessed August 29, 2025, https://www.cureepilepsy.org/understanding-epilepsy/treatments/epilepsy-medications/phenobarbital/
15. Phenobarbital | C12H12N2O3 | CID 4763 - PubChem, accessed August 29, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Phenobarbital
16. Phenobarbital sodium | DrugBank Online, accessed August 29, 2025, https://go.drugbank.com/salts/DBSALT001491
17. Phenobarbital: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed August 29, 2025, https://www.medcentral.com/drugs/monograph/8689-382007/phenobarbital-oral
18. Phenobarbital: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 29, 2025, https://go.drugbank.com/drugs/DB01174
19. CAS Number 50-06-6 | Phenobarbital - Spectrum Chemical, accessed August 29, 2025, https://www.spectrumchemical.com/cas/50-06-6
20. phenobarbital | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 29, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2804
21. Phenobarbital - brand name list from Drugs.com, accessed August 29, 2025, https://www.drugs.com/ingredient/phenobarbital.html
22. 3D structure for Phenobarbital (DB01174) | DrugBank Online, accessed August 29, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB01174
23. Phenobarbital | C12H12N2O3 - ChemSpider, accessed August 29, 2025, https://www.chemspider.com/Chemical-Structure.4599.html
24. Phenobarbital 50-06-6 - Sigma-Aldrich, accessed August 29, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/p1636
25. Phenobarbital - StatPearls - NCBI Bookshelf, accessed August 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK532277/
26. What is the mechanism of Phenobarbital? - Patsnap Synapse, accessed August 29, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-phenobarbital
27. GABAA receptor - Wikipedia, accessed August 29, 2025, https://en.wikipedia.org/wiki/GABAA_receptor
28. Gaba receptors & drugs acting on them | PPTX - SlideShare, accessed August 29, 2025, https://www.slideshare.net/slideshow/gaba-receptors-drugs-acting-on-them/85749721
29. How theories evolved concerning the mechanism of action of barbiturates - PubMed, accessed August 29, 2025, https://pubmed.ncbi.nlm.nih.gov/23205959/
30. Clinical Pharmacology of Phenobarbital in Infants and Children - Auctores | Journals, accessed August 29, 2025, https://www.auctoresonline.org/article/clinical-pharmacology-of-phenobarbital-in-infants-and-children
31. Phenobarbital: MedlinePlus Drug Information, accessed August 29, 2025, https://medlineplus.gov/druginfo/meds/a682007.html
32. Phenobarbital - Epilepsy Ontario, accessed August 29, 2025, https://epilepsyontario.org/about-epilepsy/treatments/medications/phenobarbital/
33. Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. | DrugBank Online, accessed August 29, 2025, https://go.drugbank.com/articles/A35557
34. phenobarbital - PharmGKB, accessed August 29, 2025, https://www.clinpgx.org/chemical/PA450911
35. Phenobarbital (CAS 50-06-6) - Cayman Chemical, accessed August 29, 2025, https://www.caymanchem.com/product/9001494/phenobarbital
36. PHENOBARBITAL = PB oral - MSF Medical Guidelines, accessed August 29, 2025, https://medicalguidelines.msf.org/en/viewport/EssDr/english/phenobarbital-oral-16684423.html
37. Barbiturate overdose - Wikipedia, accessed August 29, 2025, https://en.wikipedia.org/wiki/Barbiturate_overdose
38. Phenobarbital (Phenobarbitone) - Austin Health, accessed August 29, 2025, https://www.austin.org.au/Assets/Files/Phenobarbital%20(Phenobarbitone)_July%202024.pdf
39. Label: PHENOBARBITAL tablet - DailyMed, accessed August 29, 2025, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=746d5afa-d2f2-475f-b318-d4003c6d6924
40. Barbiturate toxicity - LITFL, accessed August 29, 2025, https://litfl.com/barbiturate-toxicity/
41. www.ncbi.nlm.nih.gov, accessed August 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK532277/#:~:text=Phenobarbital%20is%20a%20member%20of,addressing%20benzodiazepine%20and%20alcohol%20withdrawal.
42. PHENOBARBITAL TABLETS, USP - DailyMed, accessed August 29, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1fd1c79c-37c3-40b8-983b-f88bb92e9ce7
43. Established and emerging GABAA receptor pharmacotherapy for epilepsy - Frontiers, accessed August 29, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1341472/full
44. PHENobarbital, PHENobarbital Sodium (Systemic) (Sedative) Monograph for Professionals - Drugs.com, accessed August 29, 2025, https://www.drugs.com/monograph/phenobarbital-phenobarbital-sodium-systemic-sedative.html
45. Effects of Phenobarbital Use: Short-Term, Long-Term, Side Effects, and Treatment, accessed August 29, 2025, https://drugabuse.com/drugs/phenobarbital/effects-use/
46. Phenobarbital: Side Effects, Safety & Dangers - American Addiction Centers, accessed August 29, 2025, https://americanaddictioncenters.org/phenobarbital-abuse/long-term-side-effects
47. accesspharmacy.mhmedical.com, accessed August 29, 2025, https://accesspharmacy.mhmedical.com/content.aspx?bookid=1514§ionid=88804843#:~:text=Phenobarbital%20has%20also%20been%20used,unconjugated%20hyperbilirubinemia%20or%20chronic%20cholestasis.
48. Phenobarbital and Primidone | Casebook in Clinical Pharmacokinetics and Drug Dosing, accessed August 29, 2025, https://accesspharmacy.mhmedical.com/content.aspx?bookid=1514§ionid=88804843
49. Evading Seizures: Phenobarbital Reintroduced as a Multifunctional Approach to End-of-Life Care - PMC - PubMed Central, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8958614/
50. Phenobarbital Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 29, 2025, https://www.drugs.com/sfx/phenobarbital-side-effects.html
51. Phenobarbital (Phenobarbital): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 29, 2025, https://www.rxlist.com/phenobarbital-drug.htm
52. Phenobarbital: Uses, Side Effects, Warnings & More - GoodRx, accessed August 29, 2025, https://www.goodrx.com/phenobarbital/what-is
53. phenobarbital, accessed August 29, 2025, https://glowm.com/resources/glowm/cd/pages/drugs/p027.html
54. Phenobarbital Uses, Side Effects & Warnings - Drugs.com, accessed August 29, 2025, https://www.drugs.com/mtm/phenobarbital.html
55. Phenobarbital Tablets, USP - DailyMed, accessed August 29, 2025, https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=894c57ee-0f5f-41a1-9e0d-3f1f8fdfc9ab&type=pdf
56. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SEZABY safely and effect - accessdata.fda.gov, accessed August 29, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215910s000lbl.pdf
57. PHENobarbital | Drug Lookup | Pediatric Care Online | American Academy of Pediatrics, accessed August 29, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5545/PHENobarbital
58. Phenobarbital (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 29, 2025, https://www.mayoclinic.org/drugs-supplements/phenobarbital-intravenous-route/description/drg-20544740
59. phenobarbital - Drug Summary - PDR.Net, accessed August 29, 2025, https://www.pdr.net/drug-summary/Phenobarbital-Tablets--15-mg--30-mg--60-mg--100-mg--phenobarbital-861
60. Phenobarbital Disease Interactions - Drugs.com, accessed August 29, 2025, https://www.drugs.com/disease-interactions/phenobarbital.html
61. Effects of new anticonvulsant medications on porphyrin synthesis in cultured liver cells: Potential implications for patients with acute porphyria - Neurology.org, accessed August 29, 2025, https://www.neurology.org/doi/10.1212/WNL.49.1.97
62. Acute Intermittent Porphyria - StatPearls - NCBI Bookshelf, accessed August 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547665/
63. Phenobarbital: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 29, 2025, https://www.rxlist.com/phenobarbital/generic-drug.htm
64. Phenobarbitone - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 29, 2025, https://www.pediatriconcall.com/drugs/phenobarbitone/868
65. Barbiturate Toxicity - StatPearls - NCBI Bookshelf, accessed August 29, 2025, https://www.ncbi.nlm.nih.gov/books/NBK499875/
66. Clinical Practice Guidelines : Phenobarbitone poisoning - The Royal Children's Hospital, accessed August 29, 2025, https://www.rch.org.au/clinicalguide/guideline_index/Phenobarbitone_poisoning/
67. Phenobarbital overdose Information | Mount Sinai - New York, accessed August 29, 2025, https://www.mountsinai.org/health-library/poison/phenobarbital-overdose
68. Phenobarbital-induced expression of cytochrome P450 genes* - Frontiers Publishing Partnerships, accessed August 29, 2025, https://www.frontierspartnerships.org/articles/10.18388/abp.2000_3962/pdf
69. CYTOCHROME P450 DRUG INTERACTION TABLE, accessed August 29, 2025, https://drug-interactions.medicine.iu.edu/Main-Table.aspx
70. Drug Interaction Report: phenobarbital, propranolol - Drugs.com, accessed August 29, 2025, https://www.drugs.com/interactions-check.php?drug_list=1846-0,1956-0&professional=1
71. 8 Phenobarbital Interactions to Watch for: Birth Control Pills, Blood Thinners, and More, accessed August 29, 2025, https://www.goodrx.com/phenobarbital/phenobarbital-interactions
72. Phenobarbital and Alcohol/Food Interactions - Drugs.com, accessed August 29, 2025, https://www.drugs.com/food-interactions/phenobarbital.html
73. Phenobarbital Interactions Checker - Drugs.com, accessed August 29, 2025, https://www.drugs.com/drug-interactions/phenobarbital.html
74. Sezaby (phenobarbital) dosing, indications, interactions, adverse effects, and more, accessed August 29, 2025, https://reference.medscape.com/drug/sezaby-phenobarbital-343017
75. What Is Phenobarbital Abuse? - American Addiction Centers, accessed August 29, 2025, https://americanaddictioncenters.org/phenobarbital-abuse
76. Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes., accessed August 29, 2025, https://www.unodc.org/documents/lpo-brazil/noticias/2011/03-marco/Jife/Report_of_the_Board_on_the_availability_of_controlled_substances.pdf
77. Undue regulatory control on phenobarbital—an important yet overlooked reason for the epilepsy treatment gap - PMC, accessed August 29, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6858857/
78. 21 CFR 1308.14 -- Schedule IV. - eCFR, accessed August 29, 2025, https://www.ecfr.gov/current/title-21/chapter-II/part-1308/subject-group-ECFRf62f8e189108c4d/section-1308.14
79. Controlled Substance by DEA Code Number, accessed August 29, 2025, https://www.deadiversion.usdoj.gov/schedules/orangebook/d_cs_drugcode.pdf
80. Phenobarbital (phenobarbitone) - Right Decisions, accessed August 29, 2025, https://rightdecisions.scot.nhs.uk/scottish-palliative-care-guidelines/medicines-information/phenobarbital-phenobarbitone/
81. Controlled drugs in care homes - Care Quality Commission, accessed August 29, 2025, https://www.cqc.org.uk/guidance-providers/adult-social-care/controlled-drugs-care-homes
82. Controlled Drugs and Substances Act - Wikipedia, accessed August 29, 2025, https://en.wikipedia.org/wiki/Controlled_Drugs_and_Substances_Act
83. Controlled Drugs and Substances Act ( SC 1996, c. 19) - Laws.justice.gc.ca, accessed August 29, 2025, https://laws-lois.justice.gc.ca/eng/acts/c-38.8/page-12.html
84. Ontario's Opioid Strategy | ontario.ca, accessed August 29, 2025, https://www.ontario.ca/page/ontarios-opioid-strategy
85. Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes - INCB, accessed August 29, 2025, https://www.incb.org/documents/Publications/AnnualReports/AR2015/English/Supp/AR15_Availability_E_Chapter_III_B.pdf